+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-vertigo Drugs Market - Global Forecast 2025-2030- Product Image
Anti-vertigo Drugs Market - Global Forecast 2025-2030- Product Image
Sale

Anti-vertigo Drugs Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6142534
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The anti-vertigo drug market is undergoing significant evolution, spurred by shifting regulatory requirements, innovative drug delivery technologies, and intensified focus on patient-centric therapies. For senior decision-makers, understanding these market forces and their operational impact is critical to shaping successful strategies and sustaining competitive advantage.

Market Snapshot: Anti-vertigo Drug Market

The global anti-vertigo drug market remains highly dynamic, characterized by ongoing advancements across multiple therapeutic classes and a wide spectrum of clinical applications. Market players are capitalizing on the rising need for rapid symptom relief, robust safety profiles, and enhanced patient adherence. Shifting payer expectations, increased investment in real-world evidence, and tailored distribution models continue to drive innovation and competition. The conflict between escalating production costs and the demand for accessible treatments adds further complexity, making this a multifaceted landscape for executive consideration.

Scope & Segmentation

This report provides a detailed analysis of the anti-vertigo drug market across product types, drug classes, clinical indications, distribution networks, end-user settings, and regional landscapes.

  • Product Forms: Capsules (hard, soft), injections (intramuscular, intravenous), liquids (suspensions, syrups), tablets (immediate and sustained release).
  • Drug Classes: Anticholinergics (scopolamine), antihistamines (dimenhydrinate, meclizine), benzodiazepines (clonazepam, diazepam), calcium channel blockers (cinnarizine, flunarizine), corticosteroids (dexamethasone, prednisone).
  • Indications: Benign paroxysmal positional vertigo, labyrinthitis, motion sickness, Ménière’s disease, vestibular neuritis.
  • Distribution Channels: Hospital pharmacies (general, specialty), online pharmacies (e-commerce platforms, manufacturer sites), retail pharmacies (chain, independent), specialty pharmacies (ENT focused).
  • End Users: Ambulatory care centers (day surgery, urgent care), clinics (ENT, outpatient), home care (caregiver or self administration), hospitals (general, specialty).
  • Regions: Americas (including the United States and major states), Europe, Middle East & Africa (UK, Germany, France, and others), Asia-Pacific (China, India, Japan, Australia, and more).
  • Key Companies: Abbott Laboratories, Viatris Inc., Sandoz International GmbH, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Novartis International AG, Merck & Co., Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd.

Key Takeaways for Senior Decision-Makers

  • Regulatory bodies now prioritize real-world data and post-marketing surveillance, compelling manufacturers to incorporate remote monitoring and digital health technologies into development and commercialization strategies.
  • Market segmentation by product form and indication supports targeted go-to-market strategies, helping companies align clinical offerings to patient and provider needs while optimizing distribution across institutional and direct-to-consumer channels.
  • The successful adoption of sustained-release formulations and advanced delivery systems promises improved patient adherence, offering differentiation for brands seeking leadership in specialized therapies.
  • Emergence of region-specific dynamics, notably in Asia-Pacific and EMEA, is accelerating adoption of both branded and generic anti-vertigo therapies. This heightens the importance of tailored supply chains, diverse pricing strategies, and regional compliance initiatives.
  • Strategic alliances, from licensing to research partnerships, remain central for expanding product portfolios, accelerating commercialization timelines, and navigating complex regulatory pathways in both mature and emerging markets.

Tariff Impact: Navigating 2025 US Import Adjustments

In 2025, revised US tariff measures are significantly influencing the anti-vertigo drug supply chain and manufacturing costs. Increased import duties on critical pharmaceutical ingredients have led companies to re-evaluate procurement, diversify sourcing, and invest in domestic production capabilities. These shifts not only help mitigate volatility but drive innovations in supply chain resilience, though added complexity and longer lead times persist. Proactive engagement between manufacturers, suppliers, and regulatory authorities is helping to minimize disruptions in patient access and support smoother market entry.

Methodology & Data Sources

This anti-vertigo drug market analysis is based on a multi-phased research approach, integrating secondary data from regulatory filings, scientific literature, and proprietary databases with primary expert interviews. This triangulation ensures robust, actionable insights for strategic planning and investment.

Why This Report Matters

  • Enables executive teams to benchmark market segmentation, regional trends, and competitor moves across all key areas—from supply chain to product innovation.
  • Delivers clarity on regulatory impacts, patient-centric delivery models, and implications of new US tariff structures for risk mitigation and growth strategy.

Conclusion

Senior leaders equipped with the findings of this report can sharpen their strategic focus and adapt quickly to dynamic market shifts in the anti-vertigo drug sector. Staying ahead requires ongoing alignment of clinical, commercial, and operational strategies with evolving global paradigms.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of pharmacogenomic profiling to personalize anti-vertigo drug regimens and improve outcomes
5.2. Development of intranasal delivery platforms for rapid symptomatic relief in acute vertigo episodes
5.3. Emergence of fixed-dose combination therapies targeting vestibular compensation and nausea management
5.4. Increased investment in neuroprotective small molecules to prevent chronic vestibular dysfunction progression
5.5. Regulatory initiatives accelerating approval pathways for novel vestibular disorder treatments
5.6. Integration of digital balance assessment tools with pharmacotherapy to enhance treatment monitoring
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-vertigo Drugs Market, by Product Form
8.1. Introduction
8.2. Capsules
8.2.1. Hard Capsules
8.2.2. Soft Capsules
8.3. Injection
8.3.1. Intramuscular
8.3.2. Intravenous
8.4. Liquid
8.4.1. Suspension
8.4.2. Syrup
8.5. Tablets
8.5.1. Immediate Release
8.5.2. Sustained Release
9. Anti-vertigo Drugs Market, by Drug Class
9.1. Introduction
9.2. Anticholinergics
9.2.1. Scopolamine
9.3. Antihistamines
9.3.1. Dimenhydrinate
9.3.2. Meclizine
9.4. Benzodiazepines
9.4.1. Clonazepam
9.4.2. Diazepam
9.5. Calcium Channel Blockers
9.5.1. Cinnarizine
9.5.2. Flunarizine
9.6. Corticosteroids
9.6.1. Dexamethasone
9.6.2. Prednisone
10. Anti-vertigo Drugs Market, by Indication
10.1. Introduction
10.2. Benign Paroxysmal Positional Vertigo
10.3. Labyrinthitis
10.4. Motion Sickness
10.5. Ménière’s Disease
10.6. Vestibular Neuritis
11. Anti-vertigo Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.2.1. General Hospitals
11.2.2. Specialty Hospitals
11.3. Online Pharmacies
11.3.1. E-Commerce Platforms
11.3.2. Manufacturer Sites
11.4. Retail Pharmacies
11.4.1. Chain Pharmacies
11.4.2. Independent Pharmacies
11.5. Specialty Pharmacies
11.5.1. ENT Specialty Pharmacies
12. Anti-vertigo Drugs Market, by End User
12.1. Introduction
12.2. Ambulatory Care Centers
12.2.1. Day Surgery Centers
12.2.2. Urgent Care Centers
12.3. Clinics
12.3.1. ENT Clinics
12.3.2. Outpatient Centers
12.4. Home Care Settings
12.4.1. Caregiver Administration
12.4.2. Self Administration
12.5. Hospitals
12.5.1. General Hospitals
12.5.2. Specialty Hospitals
13. Americas Anti-vertigo Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anti-vertigo Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anti-vertigo Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. Viatris Inc.
16.3.3. Sandoz International GmbH
16.3.4. Pfizer Inc.
16.3.5. Sanofi S.A.
16.3.6. Teva Pharmaceutical Industries Ltd.
16.3.7. Novartis International AG
16.3.8. Merck & Co., Inc.
16.3.9. Bayer AG
16.3.10. Dr. Reddy’s Laboratories Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTI-VERTIGO DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTI-VERTIGO DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTI-VERTIGO DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ANTI-VERTIGO DRUGS MARKET: RESEARCHAI
FIGURE 26. ANTI-VERTIGO DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. ANTI-VERTIGO DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. ANTI-VERTIGO DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-VERTIGO DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HARD CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HARD CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SOFT CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SOFT CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SCOPOLAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SCOPOLAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DIMENHYDRINATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DIMENHYDRINATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY MECLIZINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY MECLIZINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CLONAZEPAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CLONAZEPAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DIAZEPAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DIAZEPAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CINNARIZINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CINNARIZINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY FLUNARIZINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY FLUNARIZINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY PREDNISONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY BENIGN PAROXYSMAL POSITIONAL VERTIGO, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY BENIGN PAROXYSMAL POSITIONAL VERTIGO, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY LABYRINTHITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY LABYRINTHITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY MOTION SICKNESS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY MOTION SICKNESS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY MÉNIÈRE’S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY MÉNIÈRE’S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY VESTIBULAR NEURITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY VESTIBULAR NEURITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY MANUFACTURER SITES, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY MANUFACTURER SITES, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ENT SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ENT SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DAY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY DAY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY ENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY CAREGIVER ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 156. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 157. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 158. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 159. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 160. GLOBAL ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 201. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 202. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 203. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 204. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 205. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 206. AMERICAS ANTI-VERTIGO DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 247. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 248. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 249. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 250. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 251. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 252. UNITED STATES ANTI-VERTIGO DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 253. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 254. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 255. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 256. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 257. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 258. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 259. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 260. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 261. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 262. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 263. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 264. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 265. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 266. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 267. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2018-2024 (USD MILLION)
TABLE 268. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2025-2030 (USD MILLION)
TABLE 269. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 270. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 271. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 272. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 273. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 274. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 275. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 280. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 281. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 282. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 283. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 284. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 285. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2024 (USD MILLION)
TABLE 286. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2025-2030 (USD MILLION)
TABLE 287. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
TABLE 290. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2030 (USD MILLION)
TABLE 291. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 292. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 293. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 294. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 295. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 296. CANADA ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 297. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
TABLE 298. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
TABLE 299. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2018-2024 (USD MILLION)
TABLE 300. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY CAPSULES, 2025-2030 (USD MILLION)
TABLE 301. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 302. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 303. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
TABLE 304. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY LIQUID, 2025-2030 (USD MILLION)
TABLE 305. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2018-2024 (USD MILLION)
TABLE 306. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY TABLETS, 2025-2030 (USD MILLION)
TABLE 307. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 308. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 309. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2018-2024 (USD MILLION)
TABLE 310. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTICHOLINERGICS, 2025-2030 (USD MILLION)
TABLE 311. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2018-2024 (USD MILLION)
TABLE 312. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY ANTIHISTAMINES, 2025-2030 (USD MILLION)
TABLE 313. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2018-2024 (USD MILLION)
TABLE 314. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY BENZODIAZEPINES, 2025-2030 (USD MILLION)
TABLE 315. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2024 (USD MILLION)
TABLE 316. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2025-2030 (USD MILLION)
TABLE 317. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2024 (USD MILLION)
TABLE 318. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY CORTICOSTEROIDS, 2025-2030 (USD MILLION)
TABLE 319. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 320. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 321. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 324. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 325. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 326. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 327. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 328. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 329. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2018-2024 (USD MILLION)
TABLE 330. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, 2025-2030 (USD MILLION)
TABLE 331. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 332. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 333. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
TABLE 334. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2030 (USD MILLION)
TABLE 335. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 336. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 337. MEXICO ANTI-VERTIGO DRUGS MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-vertigo Drugs market report include:
  • Abbott Laboratories
  • Viatris Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis International AG
  • Merck & Co., Inc.
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd.

Related Topics

Related Reports

Vertigo Market Report and Forecast 2025-2034 - Product Image

Vertigo Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Vertigo Drugs - Global Strategic Business Report - Product Image

Vertigo Drugs - Global Strategic Business Report

  • Report
  • 267 Pages
  • Global
From
Vertigo Drugs Market 2024-2028 - Product Image

Vertigo Drugs Market 2024-2028

  • Report
  • 157 Pages
  • Global
From
Vertigo - Global Clinical Trials Review, 2025 - Product Image

Vertigo - Global Clinical Trials Review, 2025

  • Clinical Trials
  • 155 Pages
  • Global
From
Anti-Parkinson's Disease Drugs Market - Global Forecast 2025-2030 - Product Image

Anti-Parkinson's Disease Drugs Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.